Date published: 2026-5-30

1-800-457-3801

SCBT Portrait Logo
Seach Input

Olfr157 Inhibitors

Olfr157 inhibitors are a specialized class of chemical compounds designed to specifically target and inhibit the activity of the Olfr157 protein, a member of the olfactory receptor family within the G-protein-coupled receptor (GPCR) superfamily. Olfactory receptors like Olfr157 are crucial for the detection of odorant molecules, initiating the sensory processes that lead to the perception of smell. These receptors are expressed in the membranes of olfactory sensory neurons in the nasal epithelium and are responsible for binding to specific odorant molecules from the environment. Once an odorant binds to Olfr157, the receptor undergoes a conformational change that triggers a signal transduction pathway, ultimately leading to the generation of an electrical signal that is sent to the brain. This signal contributes to the brain's ability to recognize and interpret different smells. Inhibitors of Olfr157 are small molecules that are designed to bind to the receptor's odorant-binding site or other critical regions, preventing the receptor from interacting with its natural ligands and thereby blocking the initiation of the olfactory signal.

The development of Olfr157 inhibitors involves extensive research into the receptor's structural and functional characteristics. Researchers often employ high-throughput screening techniques to identify potential inhibitory compounds that can effectively bind to Olfr157 and disrupt its function. These lead compounds are then optimized through structure-activity relationship (SAR) studies, which involve modifying their chemical structures to enhance binding affinity, specificity, and stability. The chemical architecture of Olfr157 inhibitors is diverse, often featuring functional groups that facilitate strong and specific interactions with the receptor, such as hydrogen bonds, hydrophobic contacts, and van der Waals forces. Advanced structural biology techniques, including X-ray crystallography and nuclear magnetic resonance (NMR) spectroscopy, are utilized to visualize these interactions at an atomic level, providing insights that guide the design and refinement of these inhibitors. Achieving high selectivity is a key objective in the development of Olfr157 inhibitors, ensuring that these compounds specifically target Olfr157 without affecting other olfactory receptors or GPCRs that share similar structural features. This selectivity is crucial for enabling precise modulation of Olfr157 activity, allowing researchers to explore its specific role in olfactory perception and to gain a deeper understanding of the molecular mechanisms underlying the sense of smell.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Sorafenib

284461-73-0sc-220125
sc-220125A
sc-220125B
5 mg
50 mg
500 mg
$57.00
$100.00
$250.00
129
(3)

Targets multiple kinases; may disrupt cell signaling and angiogenesis linked to Olfr157.

Gefitinib

184475-35-2sc-202166
sc-202166A
sc-202166B
sc-202166C
100 mg
250 mg
1 g
5 g
$63.00
$114.00
$218.00
$349.00
74
(2)

EGFR inhibitor; could alter signaling pathways related to Olfr157.

Lapatinib

231277-92-2sc-353658
100 mg
$420.00
32
(1)

Dual EGFR and HER2 inhibitor; potentially influences pathways associated with Olfr157.

Pazopanib

444731-52-6sc-396318
sc-396318A
25 mg
50 mg
$130.00
$182.00
2
(1)

Inhibits VEGFR, PDGFR, and KIT; may affect pathways involved in Olfr157 regulation.

Erlotinib Hydrochloride

183319-69-9sc-202154
sc-202154A
10 mg
25 mg
$75.00
$121.00
33
(1)

EGFR inhibitor; could modify signaling pathways that Olfr157 is part of.

Vandetanib

443913-73-3sc-220364
sc-220364A
5 mg
50 mg
$167.00
$1353.00
(1)

Inhibits RET, VEGFR, and EGFR; may impact cell signaling pathways linked to Olfr157.

Sunitinib Malate

341031-54-7sc-220177
sc-220177A
sc-220177B
10 mg
100 mg
3 g
$197.00
$520.00
$1093.00
4
(1)

Multi-targeted receptor tyrosine kinase inhibitor; might affect Olfr157 through angiogenesis control.

Afatinib

439081-18-2sc-364398
sc-364398A
5 mg
10 mg
$114.00
$198.00
13
(2)

Irreversible EGFR inhibitor; could impact signaling pathways involving Olfr157.

BIBF1120

656247-17-5sc-364433
sc-364433A
5 mg
10 mg
$184.00
$321.00
2
(0)

Inhibits FGFR, VEGFR, PDGFR; potentially affects pathways related to Olfr157.

Dasatinib

302962-49-8sc-358114
sc-358114A
25 mg
1 g
$70.00
$145.00
51
(1)

BCR-ABL kinase inhibitor; may influence signaling pathways that interact with Olfr157.